Menin-MLL protein-protein interaction inhibitors: a patent review (2021-present) [0.03%]
Menin-MLL蛋白-蛋白相互作用抑制剂专利回顾(2021-至今)
Fang Wang,Zhe Yang,Yujie Wu et al.
Fang Wang et al.
Introduction: Acute leukemia harboring rearrangement of the Mixed lineage leukemia (MLL) and/or mutation of the nucleophosmin is a type of poorly prognostic and highly malignant leukemia which is extremely difficult to tr...
Coumarin derivatives as therapeutic candidates: a review of their updated patents (2017-present) [0.03%]
香豆素衍生物作为治疗候选药物：对其最新专利（2017-至今）的回顾
Kalfagianni Malamati-Konstantina,Hadjipavlou-Litina Dimitra
Kalfagianni Malamati-Konstantina
Introduction: Coumarins constitute a family of heterocyclic compounds that have been extensively studied as possible drugs in the pharmaceutical research to support human health. ...
Guizhen Zhou,Chuan Zhou,Xinyi Ma et al.
Guizhen Zhou et al.
Introduction: SOS1 is a crucial guanine nucleotide exchange factor for KRAS. It facilitates the transition of KRAS from inactive GDP-bound state to active GTP-bound state. The activation of KRAS triggers downstream signal...
An update patent review of MDM2-p53 interaction inhibitors (2019-2023) [0.03%]
MDM2-p53互作抑制剂的专利更新(2019-2023)
Aleksandra Twarda-Clapa
Aleksandra Twarda-Clapa
Introduction: The activity of the major tumor suppressor protein p53 is disrupted in nearly all human cancer types, either by mutations in TP53 gene or by overexpression of its negative regulator, Mouse Double Minute 2 (M...
Mycobacterium tuberculosis inhibitors: an updated patent review (2021-present) [0.03%]
结核分枝杆菌抑制剂专利回顾（2021至今）
Salvucci Benedetta,Francesco Vallini,Michela Guida et al.
Salvucci Benedetta et al.
Introduction: Tuberculosis (TB) remains a major global health issue, causing around 10 million new cases and 1.3 million deaths in 2022. The challenge is compounded by multidrug-resistant (MDR) and extensively drug-resist...
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019-2023 update of the patent literature [0.03%]
用于治疗糖尿病并发症的醛糖还原酶抑制剂的专利文献2019-2023年度更新综述
Bianca Laura Bernardoni,Ilaria D&#x;Agostino,Fabio Scianò et al.
Bianca Laura Bernardoni et al.
Introduction: Aldose reductase (AKR1B1, EC: 1.1.1.21) is a recognized target for the treatment of long-term diabetic complications since its activation in hyperglycemia and role in the polyol pathway. In particular, the t...
Giulia Bononi,Valeria Di Bussolo,Tiziano Tuccinardi et al.
Giulia Bononi et al.
Introduction: Lactate dehydrogenase (LDH) is a key enzyme in glycolysis responsible for the conversion of pyruvate into lactate and vice versa. Lactate plays a crucial role in tumor progression and metastasis; therefore, ...
Correction [0.03%]
改正通知书
Published Erratum
Expert opinion on therapeutic patents. 2024 Sep 27:1-2. DOI:10.1080/13543776.2024.2410095 2024
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present) [0.03%]
针对IL-1受体相关激酶4(IRAK4)的治疗化合物(2019年至今专利回顾)
Fei Xiang
Fei Xiang
Background: It is more than two decades since IRAK4, a promising target for therapies against various medical conditions, was first reported, but no compounds targeting this enzyme are active on the market or under late-s...
Pyruvate kinase modulators as a therapy target: an updated patent review 2018-2023 [0.03%]
丙酮酸激酶调节剂作为治疗靶点的专利回顾（2018-2023）
Sevki Adem,Azhar Rasul,Saba Riaz et al.
Sevki Adem et al.
Introduction: Cancer cells adopt a glycolytic phenotype to fulfill their energy needs in unfavorable conditions. In metabolic rewiring, cancer cells upregulate the expression of glycolytic pathway regulators including glu...